Wire · opportunities
Biotech experts call for FDA changes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 July 2026 · Fusion42 review
FDA has lost 3,000+ employees under RFK Jr., including key division heads, amid staffing cuts and political leadership turnover; biotech industry calls for science-based drug review standards and warns that regulatory predictability is critical to keeping development pipelines alive.
This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
Your clinical trial timeline and approval odds now depend on who the FDA hires in the next 90 days, not on the science alone. The agency is rebuilding its review staff from scratch while three competing candidates await nomination as commissioner—pick the wrong leader and you're waiting an extra 18 months; pick right and cell therapy gets a fast lane.
◆ Related on Wire
◆ Topics